Navigation Links
Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
Date:2/20/2008

SAN DIEGO, Feb. 20 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will report fourth quarter and full year 2007 financial results after the NASDAQ Global Market closes on Wednesday, February 27, 2008. That same afternoon, Jack Lief, Arena's President and Chief Executive Officer, and Robert E. Hoffman, Arena's Vice President, Finance and Chief Financial Officer, will host a conference call at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the financial results for the fourth quarter and full year 2007 and to provide 2008 financial guidance and a corporate update.

The conference call may be accessed by dialing 866.356.4281 for domestic callers and 617.597.5395 for international callers. Please specify to the operator that you would like to join the "Arena Fourth Quarter and Full Year Earnings Call." The participant code for the call is 19957700. The conference call will be webcast live under the investor relations section of Arena's website at http://www.arenapharm.com, and will be archived there for 30 days following the call. Please connect to Arena's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds tar
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
2. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
3. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
4. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
5. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
6. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
9. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
11. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... A new market research report detailing ... from Strategic Consulting, Inc., the leading information resource ... Review, Fourth Edition: Global Review of Microbiology Testing ... compares microbiology test volumes, market values and methods ... and forecasts future volumes and market values through ...
(Date:8/28/2014)... Diego, CA (PRWEB) August 28, 2014 ... Pipette.com is offering a promotion for Eppendorf ... Pipette.com customers to purchase the highest quality tubes ... Tubes are ideal for customers doing chemical, medical, ... lab technicians who are not regularly able to ...
(Date:8/27/2014)... TX (PRWEB) August 27, 2014 Green ... million in Series B funding and secured Otter Capital ... investment capital will accelerate commercialization of GGI’s Agriplier™ technology, ... crop types. , “Since our first meeting, we ... to the biological product space,” said Alan Sobba, President ...
(Date:8/27/2014)... , Aug. 27, 2014 ... report is available in its catalogue: ... http://www.reportlinker.com/p02316661/Global-Biodegradable-Packaging-Materials-Market-2014-2018.html ... are materials that are readily decomposed by ... from conventional non-degradable packaging in terms of ...
Breaking Biology Technology:2 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 3Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 3Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3Global Biodegradable Packaging Materials Market 2014-2018 2Global Biodegradable Packaging Materials Market 2014-2018 3Global Biodegradable Packaging Materials Market 2014-2018 4Global Biodegradable Packaging Materials Market 2014-2018 5Global Biodegradable Packaging Materials Market 2014-2018 6Global Biodegradable Packaging Materials Market 2014-2018 7
... Hosts Three Customer Audits, Continues Growth Strategy ... Industry-Leading Software Tools, MOUNTAIN VIEW, Calif., Dec. ... leading provider of software, strategic,consulting, and regulatory services ... global biopharmaceutical companies,have performed audits of its Reporting ...
... ... - Lead compound AEG40826 works synergistically with HGS TRAIL receptor ... -, - IAP inhibitors also show promise alone and in combination ... agents across broad range of cancers -, ROCKVILLE, Md. and MONTREAL, Quebec, ...
... 20 Human Genome,Sciences, Inc. (Nasdaq: HGSI ... patients in a Phase 2 clinical trial of ... and carboplatin as,first-line therapy in patients with advanced ... patients who are newly diagnosed with non-small cell,lung ...
Cached Biology Technology:Pharsight's Reporting and Analysis Services Business Reaches Quality Assurance Milestone 2Pharsight's Reporting and Analysis Services Business Reaches Quality Assurance Milestone 3Pharsight's Reporting and Analysis Services Business Reaches Quality Assurance Milestone 4Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs 2Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs 3Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs 4Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs 5Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs 6Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy 2Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy 3Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy 4Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy 5Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy 6
(Date:8/27/2014)... Using functional near infrared spectroscopy (fNIRS), Kessler Foundation ... people with multiple sclerosis (MS) and healthy controls. ... brain activation was studied using fNIRS while participants ... cognition using functional near infrared spectroscopy (fNIRS) in ... by Brain Imaging and Behavior . Authors ...
(Date:8/27/2014)... 400 million years ago a group of fish began exploring ... and mammals. But just how these ancient fish used their ... evolutionary processes were at play remain scientific mysteries. , ... , turned to a living fish, called Polypterus , ... attempted to walk out of the water. Polypterus ...
(Date:8/27/2014)... is easier when it is related to ability that ... learn a new melody more easily than learning how ... the Center for the Neural Basis of Cognition (CNBC)a ... Mellon Universityhave discovered a fundamental constraint in the brain ... cover story in the Aug. 28, 2014, issue of ...
Breaking Biology News(10 mins):Kessler Foundation researchers publish first study of brain activation in MS using fNIRS 2Walking fish reveal how our ancestors evolved onto land 2Pitt and Carnegie Mellon engineers discover why learning can be difficult 2Pitt and Carnegie Mellon engineers discover why learning can be difficult 3
... PARK, MD, April 7, 2009 -- Roughly 20 percent ... homes, businesses, and other private and public spaces. Though ... also presents a tremendous opportunity for savings. Improving the ... little -- could translate into dramatically lower energy usage ...
... microbes that live within the plumbing of deep-sea mud ... resemble those in extraterrestrial environments and early Earth. The ... Foundation (NSF), was conducted in an area where clusters ... that support food chains independently of the Sun. ...
... researcher, Dr. Mark Flynn,s high-speed flywheel motor controller is ... the world. Flynn,s design has been incorporated into energy ... and sold by VYCON Inc. The 8,000 RTG ... significantly to port emissions and, as such, have ...
Cached Biology News:Cheap and efficient white light LEDs new design described in AIP's Journal of Applied Physics 2Cheap and efficient white light LEDs new design described in AIP's Journal of Applied Physics 3Better living through chemistry 2Better living through chemistry 3Saving energy and the environment with Flywheels 2
384 Cluster Tube Racks...
...
Request Info...
... Partially purified chicken intestinal cytoplasmic ... D receptor (VDR) from human, rat, ... tissues. This antibody does not ... MA1-710 detects both the occupied ...
Biology Products: